Showing 6431-6440 of 7178 results for "".
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,
- Sernivo Spray Hits Pharmacy Shelveshttps://practicaldermatology.com/news/sernivo-spray-hits-pharmacy-shelves/2458544/Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% was approved by the Food and Drug Administration (F
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- ASDSA Releases New Sun-Safety Model Legislationhttps://practicaldermatology.com/news/asdsa-releases-new-sun-safety-model-legislation/2458548/New model legislation from American Society for Dermatologic Surgery Association (ASDSA) provides state governments with a framework to permit the use of sunscreens in school and camp settings. The
- New Nair Survey Shows Unwanted Body Hair is No Confidence Boosterhttps://practicaldermatology.com/news/new-nair-survey-shows-unwanted-body-hair-is-no-confidence-booster/2458552/Just shy of 80 percent of women are more confident when they do not have unwanted body hair, according to a recent online survey conducted by Harris Poll on behalf of Church & Dwight Co., Inc., the makers of Nair™. Who Wears Short Shorts? Nair for Short Shorts</
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,
- Thermi to Sell, Market Silhouette InstaLift™ in the UShttps://practicaldermatology.com/news/thermi-to-sell-market-silhouette-instalift-in-the-us/2458557/Sinclair and Thermi are teaming up for the sales, marketing, and distribution of Silhouette InstaLift™ in the US. Sinclair granted Thermi exclusive four-year distribution rights for the US market unti
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human
- AAD Survey: Many Use Sunscreen Incorrectlyhttps://practicaldermatology.com/news/aad-survey-many-use-sunscreen-incorrectly/2458561/Many people don’t understand SPF numbers on product labels, and some may not be using sunscreen properly, which could increase their skin cancer risk, the American Academy of Dermatology reports. In a 2016 survey, only 32 percent of respondents knew that an SPF 30 sunscreen do